Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

This study has been completed.
Information provided by:
Central European Society for Anticancer Drug Research Identifier:
First received: May 6, 2008
Last updated: November 30, 2011
Last verified: November 2011
Primary objective: to evaluate whether the addition of sunitinib prolongates the Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving first-line gemcitabine chemotherapy.

Condition Intervention Phase
Pancreatic Cancer
Drug: Gemcitabine + Sunitinib
Drug: Gemcitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Central European Society for Anticancer Drug Research:

Primary Outcome Measures:
  • Time to Progression [ Time Frame: once all patients completed treatment ]

Secondary Outcome Measures:
  • Response Rate (RR) [ Time Frame: once all patients completed treatment ]
  • overall survival [ Time Frame: at study end ]
  • Safety [ Time Frame: at study end ]

Enrollment: 105
Study Start Date: April 2008
Study Completion Date: November 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Gemcitabine + Sunitinib
Drug: Gemcitabine + Sunitinib
Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
Drug: Gemcitabine
1.000 mg/m2 d1,8,15q4weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who suffer from locally advanced or metastatic pancreatic cancer
  • Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST).
  • ECOG performance status 0 to 1
  • Signed written informed consent.
  • White blood cell count (WBC) >= 3x10^9/L with neutrophils >= 1.5 x 10^9/L, platelet count >= 100x10^9/L, hemoglobin >= 5.6 mmol/L (9 g/dL).
  • Total bilirubin < 2 x upper limit of normal.
  • AST and ALT < 2.5 x upper limit of normal, or < 5 x upper limit of normal in case of liver metastases.
  • Serum creatinine < 1.5 x upper limit of normal
  • Normal ECG without QT prolongation

Exclusion Criteria:

  • Resectable pancreatic cancer
  • Previous chemotherapy (for adjuvant or metastatic disease)
  • Any investigational drug within the 30 days before inclusion.
  • Prior use of sunitinib or other multitarget tyrosine kinase inhibitor
  • Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.
  • Men or women of child-bearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial.
  • Clinically symptomatic brain or meningeal metastasis. (known or suspected)
  • Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin).
  • History of any of the following cardiac events within the past 6 months: myocardial infarction (including severe/unstable angina; coronary/peripheral artery bypass graft; symptomatic congestive heart failure (CHF) > NYHA Class II; cerebrovascular accident or transient ischemic attack; pulmonary embolism
  • Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90 mm Hg despite the use of up to 3 anti-hypertensive drugs
  • Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or chronic diarrhea
  • Previous malignancy (other than pancreatic cancer) in the last 5 years except basal cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder tumor [Ta, Tis and T1].
  • History of organ allograft
  • Patients requiring long-term cortisone therapy
  • Patients requiring oral anticoagulation treatment (such as marcoumar)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00673504

Städtisches Klinikum Braunschweig
Braunschweig, Germany, 38114
Universitätsklinikum Essen
Essen, Germany, 45122
Frankfurt, Germany, 60488
Klinikum der J. W. Goethe Universität; Zentrum der Inneren Medizin
Frankfurt, Germany, 60590
Internistisches Facharztzentrum
Frankfurt, Germany, 60596
Martin-Luther-Universität Halle-Wittenberg; Medizinische Fakultät
Halle (Saale), Germany, 06097
Heidelberg, Germany, 69115
Klinikum Lüdenscheid
Luedenscheid, Germany, 58515
Klinikum Nürnberg Nord
Nürnberg, Germany, 90419
Stuttgart, Germany, 70376
Kantonsspital St. Gallen
St. Gallen, Switzerland, 9007
Sponsors and Collaborators
Central European Society for Anticancer Drug Research
  More Information

Additional Information:
Responsible Party: Central European Society for Anticancer Drug Research-EWIV, Non-Profit Otrganization Oncology Identifier: NCT00673504     History of Changes
Other Study ID Numbers: C-II-004 / 2007-005022-71
Study First Received: May 6, 2008
Last Updated: November 30, 2011

Keywords provided by Central European Society for Anticancer Drug Research:
pancreatic cancer
Phase 2

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors processed this record on April 26, 2017